X. Dong, Current strategies for brain drug delivery, Theranostics, vol.8, pp.1481-1493, 2018.

S. Durmus, J. J. Hendrikx, and A. H. Schinkel, Apical ABC transporters and cancer chemotherapeutic drug disposition, Adv. Cancer Res, vol.125, pp.1-41, 2015.

J. F. Deeken and W. Löscher, The blood-brain barrier and cancer: transporters, treatment, and Trojan horses, Clin. Cancer Res, vol.13, pp.1663-1674, 2007.

W. A. Banks, From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery, Nat. Rev. Drug Discov, vol.15, pp.275-292, 2016.

N. J. Abbott, A. A. Patabendige, D. E. Dolman, S. R. Yusof, and D. J. Begley, Structure and function of the blood-brain barrier, Neurobiol. Dis, vol.37, pp.13-25, 2010.

M. D. Bock, V. Van-haver, R. E. Vandenbroucke, E. Decrock, N. Wang et al., Into rather unexplored terrain-transcellular transport across the blood-brain barrier, Glia, vol.64, pp.1097-1123, 2016.

N. J. Abbott, L. Rönnbäck, and E. Hansson, Astrocyte-endothelial interactions at the blood-brain barrier, Nat. Rev. Neurosci, vol.7, pp.41-53, 2006.

R. Shawahna, Y. Uchida, X. Declèves, S. Ohtsuki, S. Yousif et al., Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels, Mol. Pharm, vol.8, pp.1332-1341, 2011.

P. Ballard, J. W. Yates, Z. Yang, D. Kim, J. C. Yang et al., Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin. Cancer Res, vol.22, pp.5130-5140, 2016.

A. Kort, S. Durmus, R. W. Sparidans, E. Wagenaar, J. H. Beijnen et al., Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1), Pharm. Res, vol.32, pp.2205-2216, 2015.

H. Kodaira, H. Kusuhara, J. Ushiki, E. Fuse, and Y. Sugiyama, Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone, J. Pharmacol. Exp. Ther, vol.333, pp.788-796, 2010.

N. A. De-vries, T. Buckle, J. Zhao, J. H. Beijnen, J. H. Schellens et al.,

S. , Journal of Controlled Release, vol.292, pp.210-220, 2018.

P. , B. , and I. , New Drugs, vol.30, pp.443-449, 2012.

S. Agarwal, P. Manchanda, M. A. Vogelbaum, J. R. Ohlfest, and W. F. Elmquist, Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma, Drug Metab. Dispos, vol.41, pp.33-39, 2013.

D. R. Camidge, W. Pao, and L. V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nat. Rev. Clin. Oncol, vol.11, pp.473-481, 2014.

T. E. Taylor, F. B. Furnari, and W. K. Cavenee, Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance, Curr. Cancer Drug Targets, vol.12, pp.197-209, 2012.

S. Agarwal, R. Sane, R. Oberoi, J. R. Ohlfest, and W. F. Elmquist, Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain, Expert Rev. Mol. Med, vol.13, 2011.

J. How, J. Mann, A. N. Laczniak, and M. Q. Baggstrom, Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature, Clin. Lung Cancer, vol.18, pp.354-363, 2017.

O. Couture, J. Foley, N. F. Kassell, B. Larrat, and J. Aubry, Review of ultrasound mediated drug delivery for cancer treatment: updates from pre-clinical studies, Transl. Cancer Res, vol.3, pp.494-511, 2014.

H. Liu, C. Fan, C. Ting, and C. Yeh, Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview, Theranostics, vol.4, pp.432-444, 2014.

K. Hynynen, N. Mcdannold, N. Vykhodtseva, and F. A. Jolesz, Noninvasive MR imagingguided focal opening of the blood-brain barrier in rabbits, Radiology, vol.220, pp.640-646, 2001.

C. X. Deng, Targeted drug delivery across the blood-brain barrier using ultrasound technique, Ther. Deliv, vol.1, pp.819-848, 2010.

K. Hynynen, N. Mcdannold, H. Martin, F. A. Jolesz, and N. Vykhodtseva, The threshold for brain damage in rabbits induced by bursts of ultrasound in the presence of an ultrasound contrast agent (Optison), Ultrasound Med. Biol, vol.29, pp.473-481, 2003.

A. Carpentier, M. Canney, A. Vignot, V. Reina, K. Beccaria et al., Clinical trial of blood-brain barrier disruption by pulsed ultrasound, Sci. Transl. Med, vol.8, pp.343-345, 2016.

F. J. Sharom, Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function, Front. Oncol, vol.4, 2014.

O. Van-tellingen, B. Yetkin-arik, M. C. De-gooijer, P. Wesseling, T. Wurdinger et al., Overcoming the blood-brain tumor barrier for effective glioblastoma treatment, Drug Resist. Updat, vol.19, pp.1-12, 2015.

D. Mcmahon, R. Bendayan, and K. Hynynen, Acute effects of focused ultrasound-induced increases in blood-brain barrier permeability on rat microvascular transcriptome, Sci. Rep, vol.7, 2017.

M. Aryal, K. Fischer, C. Gentile, S. Gitto, Y. Zhang et al., Effects on Pglycoprotein expression after blood-brain barrier disruption using focused ultrasound and microbubbles, PLoS One, vol.12, p.166061, 2017.

H. Cho, H. Lee, M. Han, J. Choi, S. Ahn et al., Localized down-regulation of P-glycoprotein by focused ultrasound and microbubbles induced blood-brain barrier disruption in rat brain, Sci. Rep, vol.6, p.31201, 2016.

N. Tournier, B. Stieger, and O. Langer, Imaging techniques to study drug transporter function in vivo, Pharmacol. Ther, vol.189, pp.104-122, 2018.
URL : https://hal.archives-ouvertes.fr/cea-01943448

P. Kannan, C. John, S. S. Zoghbi, C. Halldin, M. M. Gottesman et al., Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications, Clin. Pharmacol. Ther, vol.86, pp.368-377, 2009.

A. Traxl, T. Wanek, S. Mairinger, J. Stanek, T. Filip et al., Breast cancer resistance protein and P-glycoprotein influence in vivo disposition of 11C-erlotinib, J. Nucl. Med, vol.56, pp.1930-1936, 2015.

N. Tournier, S. Goutal, S. Auvity, A. Traxl, S. Mairinger et al., Strategies to inhibit ABCB1-and ABCG2mediated efflux transport of erlotinib at the blood-brain barrier: a PET study on nonhuman primates, J. Nucl. Med, vol.58, pp.117-122, 2017.

R. B. Verheijen, M. M. Yaqub, E. Sawicki, O. Van-tellingen, A. A. Lammertsma et al., Molecular imaging of ABCB1/ABCG2 inhibition at the human blood brain barrier using elacridar and 11C-erlotinib PET, J. Nucl. Med, vol.59, pp.973-975, 2018.

S. Goutal, O. Langer, S. Auvity, K. Andrieux, C. Coulon et al., Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates, Drug Deliv. Transl. Res, vol.8, pp.536-542, 2018.

G. Pottier, S. Marie, S. Goutal, S. Auvity, M. Peyronneau et al., Imaging the impact of the P-glycoprotein (ABCB1) function on the brain kinetics of metoclopramide, J. Nucl. Med, vol.57, pp.309-314, 2016.

I. Bahce, E. F. Smit, M. Lubberink, A. A. Van-der-veldt, M. Yaqub et al., Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status, Clin. Cancer Res, vol.19, pp.183-193, 2013.

A. Damont, S. Goutal, S. Auvity, H. Valette, B. Kuhnast et al., Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: a [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates, Eur. J. Pharm. Sci, vol.91, pp.98-104, 2016.

M. Gerstenmayer, B. Fellah, R. Magnin, E. Selingue, and B. Larrat, Acoustic transmission factor through the rat skull as a function of body mass, frequency and position, Ultrasound Med. Biol, 2018.
URL : https://hal.archives-ouvertes.fr/cea-02043267

R. Magnin, F. Rabusseau, F. Salabartan, S. Mériaux, J. Aubry et al., Magnetic resonance-guided motorized transcranial ultrasound system for blood-brain barrier permeabilization along arbitrary trajectories in rodents, J. Ther. Ultrasound, vol.3, 2015.
URL : https://hal.archives-ouvertes.fr/cea-02043280

B. Marty, B. Larrat, M. Van-landeghem, C. Robic, P. Robert et al., Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis, J. Cereb. Blood Flow Metab, vol.32, pp.1948-1958, 2012.
URL : https://hal.archives-ouvertes.fr/cea-00739117

S. Hung, C. Yeh, T. Tsai, T. Chen, and R. Chen, A simple method for quantifying ultrasound-triggered microbubble destruction, Ultrasound Med. Biol, vol.37, pp.949-957, 2011.

P. Kannan, S. Telu, S. Shukla, S. V. Ambudkar, V. W. Pike et al., The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2), ACS Chem. Neurosci, vol.2, pp.82-89, 2011.

T. Kobus, N. Vykhodtseva, M. Pilatou, Y. Zhang, and N. Mcdannold, Safety validation of repeated blood-brain barrier disruption using focused ultrasound, Ultrasound Med. Biol, vol.42, pp.481-492, 2016.

D. Amor, S. Goutal, S. Marie, F. Caillé, M. Bauer et al., Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats, EJNMMI Res, vol.8, 2018.

P. Kannan, K. R. Brimacombe, S. S. Zoghbi, J. Liow, C. Morse et al., N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier, Drug Metab. Dispos, vol.38, pp.917-922, 2010.

E. P. Visser, J. A. Disselhorst, M. Brom, P. Laverman, M. Gotthardt et al., Spatial resolution and sensitivity of the Inveon small-animal PET scanner, J. Nucl. Med, vol.50, pp.139-147, 2009.

B. Weber, M. Winterdahl, A. Memon, B. S. Sorensen, S. Keiding et al., Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor, J. Thorac. Oncol, vol.6, pp.1287-1289, 2011.

M. D. Farwell, D. J. Chong, Y. Iida, S. A. Bae, B. Easwaramoorthy et al., Imaging P-glycoprotein function in rats using, Ann. Nucl. Med, vol.27, issue.11, pp.618-624, 2013.

A. Dréan, L. Goldwirt, M. Verreault, M. Canney, C. Schmitt et al., Blood-brain barrier, cytotoxic chemotherapies and glioblastoma, Expert. Rev. Neurother, vol.16, pp.1285-1300, 2016.

S. Marchetti, N. A. De-vries, T. Buckle, M. J. Bolijn, M. A. Van-eijndhoven et al., Effect of the ATPbinding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1?/?/Mdr1a/1b?/? (triple-knockout) and wild-type mice, Mol. Cancer Ther, vol.7, pp.2280-2287, 2008.

E. Sawicki, R. B. Verheijen, A. D. Huitema, O. Van-tellingen, J. H. Schellens et al., Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar, Drug Deliv. Transl. Res, vol.7, pp.125-131, 2017.

W. C. Kreisl, R. Bhatia, C. L. Morse, A. E. Woock, S. S. Zoghbi et al., Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar, J. Nucl. Med, vol.56, pp.82-87, 2015.

J. Liow, W. Kreisl, S. S. Zoghbi, N. Lazarova, N. Seneca et al., P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys, J. Nucl. Med, vol.50, pp.108-115, 2009.

T. Wanek, K. Römermann, S. Mairinger, J. Stanek, M. Sauberer et al., Factors governing P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier measured with positron emission tomography, Mol. Pharm, vol.12, pp.3214-3225, 2015.

S. , Journal of Controlled Release, vol.292, pp.210-220, 2018.

D. Bokor, J. B. Chambers, P. J. Rees, T. G. Mant, F. Luzzani et al., Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease, Investig. Radiol, vol.36, pp.104-109, 2001.

H. Liu, Y. Wai, W. Chen, J. Chen, P. Hsu et al., Hemorrhage detection during focused-ultrasound induced blood-brain-barrier opening by using susceptibility-weighted magnetic resonance imaging, Ultrasound Med. Biol, vol.34, pp.598-606, 2008.

T. Boissenot, A. Bordat, B. Larrat, M. Varna, H. Chacun et al., Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules, J. Control. Release, vol.264, pp.219-227, 2017.
URL : https://hal.archives-ouvertes.fr/cea-02043274

H. Pajouhesh and G. R. Lenz, Medicinal chemical properties of successful central nervous system drugs, NeuroRx, vol.2, pp.541-553, 2005.

X. Wang, Y. Jia, P. Wang, Q. Liu, and H. Zheng, Current status and future perspectives of sonodynamic therapy in glioma treatment, Ultrason. Sonochem, vol.37, pp.592-599, 2017.

S. Bussi, A. Coppo, C. Botteron, V. Fraimbault, A. Fanizzi et al., Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats, J. Magn. Reson. Imaging, vol.47, pp.746-752, 2018.

T. Minematsu and K. M. Giacomini, Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins, Mol. Cancer Ther, vol.10, pp.531-539, 2011.

N. Lazarova, S. S. Zoghbi, J. Hong, N. Seneca, E. Tuan et al., Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function, J. Med. Chem, vol.51, pp.6034-6043, 2008.

J. Park, M. Aryal, N. Vykhodtseva, Y. Zhang, and N. Mcdannold, Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption, J. Control. Release, vol.250, pp.77-85, 2017.

J. Mei, Y. Cheng, Y. Song, Y. Yang, F. Wang et al., Experimental study on targeted methotrexate delivery to the rabbit brain via magnetic resonance imagingguided focused ultrasound, J. Ultrasound Med, vol.28, pp.871-880, 2009.

H. Zeng, L. Lü, F. Wang, Y. Luo, and S. Lou, Focused ultrasound-induced bloodbrain barrier disruption enhances the delivery of cytarabine to the rat brain, J. Chemother, vol.24, pp.358-363, 2012.

L. Goldwirt, M. Canney, C. Horodyckid, J. Poupon, S. Mourah et al., Enhanced brain distribution of carboplatin in a primate model after blood-brain barrier disruption using an implantable ultrasound device, Cancer Chemother. Pharmacol, vol.77, pp.211-216, 2016.

K. Beccaria, M. Canney, L. Goldwirt, C. Fernandez, J. Piquet et al., Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits, J. Neurosurg, vol.124, pp.1602-1610, 2016.

R. W. Robey, K. M. Pluchino, M. D. Hall, A. T. Fojo, S. E. Bates et al., Revisiting the role of ABC transporters in multidrug-resistant cancer, Nat. Rev. Cancer, vol.1, 2018.

S. Cai, S. Thati, T. R. Bagby, H. Diab, N. M. Davies et al., Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer, J. Control. Release, vol.146, pp.212-218, 2010.

S. Alli, C. A. Figueiredo, B. Golbourn, N. Sabha, M. Y. Wu et al., Brainstem blood brain barrier disruption using focused ultrasound: a demonstration of feasibility and enhanced doxorubicin delivery, J. Control. Release, vol.281, pp.29-41, 2018.

S. Cisternino, C. Rousselle, C. Dagenais, and J. M. Scherrmann, Screening of multidrugresistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice, Pharm. Res, vol.18, pp.183-190, 2001.

J. P. Bankstahl, M. Bankstahl, K. Römermann, T. Wanek, J. Stanek et al., Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study, Drug Metab, vol.41, pp.754-762, 2013.

R. Sane, S. Agarwal, and W. F. Elmquist, Brain distribution and bioavailability of elacridar after different routes of administration in the mouse, Drug Metab. Dispos, vol.40, pp.1612-1619, 2012.

D. S. Miller, Regulation of ABC transporters at the blood-brain barrier, Clin. Pharmacol. Ther, vol.97, pp.395-403, 2015.

L. T. Lyle, P. R. Lockman, C. E. Adkins, A. S. Mohammad, E. Sechrest et al., Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer, Clin. Cancer Res, vol.22, pp.5287-5299, 2016.

M. Duvvuri, Y. Gong, D. Chatterji, and J. P. Krise, Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60, J. Biol. Chem, vol.279, pp.32367-32372, 2004.

R. K. Mittapalli, V. K. Manda, K. A. Bohn, C. E. Adkins, and P. R. Lockman, Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier, J. Neurosci. Methods, vol.219, pp.188-195, 2013.

C. E. Adkins, R. K. Mittapalli, V. K. Manda, M. I. Nounou, A. S. Mohammad et al., Pglycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model, Front. Pharmacol, vol.4, 2013.

T. Boissenot, A. Bordat, E. Fattal, and N. Tsapis, Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: from theoretical considerations to practical applications, J. Control. Release, vol.241, pp.144-163, 2016.

A. R. Khan, X. Yang, M. Fu, and G. Zhai, Recent progress of drug nanoformulations targeting to brain, J. Control. Release, 2018.

R. Li and Y. Xie, Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties, J. Control. Release, vol.251, pp.49-67, 2017.

S. Auvity, F. Caillé, S. Marie, C. Wimberley, M. Bauer et al., P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood-brain barrier: a PET study on non-human primates, J. Nucl. Med, vol.59, pp.1609-1615, 2018.
URL : https://hal.archives-ouvertes.fr/cea-01818347

S. Agarwal and W. F. Elmquist, Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance, Mol. Pharm, vol.9, pp.678-684, 2012.